Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative approach for all the patients affected by adverse-risk (according to ELN 2022 risk classification) [1] acute myeloid leukemia (AML), for patients affected by intermediate-risk AML with post-consolidation minimal residual disease (MRD) positivity (MRD+), [2], [3] and for refractory/relapsed AML patients in first and/or second complete remission (CR) after salvage treatment [4].
Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience
Contento C.;Di Gennaro D.;Albano F.;Musto P.
2023-01-01
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative approach for all the patients affected by adverse-risk (according to ELN 2022 risk classification) [1] acute myeloid leukemia (AML), for patients affected by intermediate-risk AML with post-consolidation minimal residual disease (MRD) positivity (MRD+), [2], [3] and for refractory/relapsed AML patients in first and/or second complete remission (CR) after salvage treatment [4].File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
